Abstract. Clusterin (CLU) is a glycoprotein involved in tumor progression, whose expression level correlates with the metastasis of renal cell carcinoma (RCC). However, the mechanism by which CLU plays an oncogenic role in RCC remains unclear. In this study, we used the human renal cancer cell 786-O as an experimental model. We knocked down CLU expression in the 786-O cells using lentiviral vector-mediated delivery of RNAi, and then compared the gene expression profiles between the knocked down CLU 786-O cells and control cells. We observed that CLU knockdown induced apoptosis and inhibited the proliferation and migration of 786-O cells. Microassay analysis revealed changes in the expression of 588 genes between the 786-O cells infected by a si-CLU lentivirus and the control cells, where 356 genes were upregulated and 232 were downregulated. Pathway analysis classified the differentially expressed genes into 17 upregulated and 12 downregulated pathways, including the PI3K/Akt, MAPK and VEGF pathways. In this study, we demonstrated that CLU acts as an oncogene in RCC by promoting cell proliferation and migration and inhibiting apoptosis. Microassay analysis may provide a platform for further characterization of the individual genes implicated in the development of RCC, providing new insights into the oncogenic role of CLU.
Introduction
Renal cell carcinoma (RCC) is the most common primary renal malignant neoplasm in adults. It accounts for ~3% of adult malignancies and 90-95% of renal neoplasms. The gold standard for RCC treatment is surgery, where nephron-sparing surgery, laparoscopic and robotic surgery and minimally invasive procedures have all decreased the morbidity of RCC (1).
However, advanced or metastatic RCC may develop resistance to chemotherapy or radiotherapy, contributing to a poor prognosis (2) . In order to develop effective therapeutic strategies for RCC, further investigations are required to understand the molecular pathogenesis of aggressive RCC.
Cluster in (CLU ), also k nown as testosterone repressed prostate message-2 or sulfated glycoprotein-2, is a glycoprotein crucial to various pathophysiological processes (3), such as tumor pathogenesis and progression. CLU is overexpressed in a variety of tumors, including in liver, pancreatic, colorectal, ovarian, prostate, bladder and kidney cancer (4) . Furthermore, CLU expression levels correlate with the metastasis of melanoma, gastric cancer, ovarian cancer and RCC (5) (6) (7) (8) . However, the molecular mechanism by which CLU plays an oncogenic role in RCC remains unclear.
Global expression analysis using microarrays may be able to monitor the expression of thousands of genes in a high-throughput manner to provide novel insights into the mechanisms of cancer initiation, progression, resistance to treatment and response to cellular microenvironments (9) . Therefore, in the present study, we used the human renal cancer cell line 786-O as an experimental model. We knocked down CLU expression in 786-O cells using lentiviral vector-mediated delivery of RNAi, and then compared the gene expression profiles of knocked down CLU 786-O cells and control cells. We demonstrated that CLU knockdown induces apoptosis and inhibits the proliferation and migration of 786-O cells. Furthermore, we identified differentially expressed genes after CLU knockdown and analyzed the related pathways in which these genes are involved.
Materials and methods
Cell culture. The 786-O cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% Gibco™ FBS (Life Technologies, Grand Island, NY, USA) at 37˚C in a standard humidified incubator containing 5% CO 2 -CAGGGAAG  TAAGTACGTCAATCTCGAGATTGACGTACTTACTTCCC  TGTTTTT-3'; 2, 5'-GCTAAAGTCCTACCAGTGGAACTCG  AGT TCCACTGGTAGGACT T TAGCT T T T T-3'; and  3, 5'-AGGGAAGTAAGTACGTCAATACTCGAGTATTGAC  GTACTTACTTCCCTTTTTT-3' . A control siRNA with non-specific sequences was also produced. These siRNAs were cloned into pGCSIL-GFP plasmids. Lentiviruses were generated by the transfection of 80% confluent HEK293T cells with recombinant pGCSIL-GFP plasmids and pHelper 1.0 and pHelper 2.0 helper plasmids (GeneChem Co., Ltd.) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Lentiviruses were harvested in serum-free medium after 2 days, filtered and concentrated in primed Centricon Plus-20 filter devices (Millipore, Billerica, MA, USA), and the titers of recombinant lentiviruses were determined. The 786-O cells were seeded in 6-well plates and grown to 60% confluence on the day of transfection. Four hours prior to transfection, cells were placed in serum-free media. The cells were transfected with a titrated siRNA vector diluted in RPMI-1640, with the addition of 1 µl polybrene. Successful knockdown of CLU was analyzed by real-time PCR and western blot analysis.
Real-time PCR assay. Total RNA was extracted from the 786-O cells using TRIzol (Invitrogen), according to the manufacturer's instructions. First-strand cDNA was generated from 2 µg total RNA using the PrimeScript RT reagent kit (Takara, Dalian, China) with random primers. Real-time PCR was performed on an ABI Prism 7300 (Applied Biosystems, Foster City, CA, USA). The specific primers were as follows: C LU, 5'-T C C G C G G CAT T C T T T G G G C G -3' a n d 5'-GCACTGGGAGGCGCCGTATT-3'; and β -acti n, 5 ' -C G G AG T C A AC G G AT T T G G T C G TAT-3 ' a n d 5'-CCTTGCACATGCCGGAGCCGT-3'. Thermal cycling was initiated with a denaturation step for 1 min at 95˚C followed by 40 cycles performed in two steps; 5 sec at 95˚C and 30 sec at 60˚C. The relative mRNA level of CLU was compared to that of β-actin and was calculated by the 2 -ΔΔCt method. Each Ct value used for these calculations was the mean of triplicate results obtained for each reaction.
Western blot analysis. The 786-O cells were lysed in RIPA buffer supplemented with protease inhibitors. The supernatant was collected for the protein concentration assay. Equal amounts of protein (30 µg) were separated in 10% SDS-polyacrylamide gels and transferred to PVDF membranes. The membranes were blocked using non-fat milk in TBST and probed with either a CLU (Abcam, Cambridge, MA, USA) or GAPDH antibody (Santa Cruz Biotech, Santa Cruz, CA, USA), followed by incubation with a secondary antibody. Immunoreactivity signals were developed using an enhanced chemiluminescence (ECL) kit (GE Healthcare, Piscataway, NJ, USA).
Cell proliferation assay. The proliferation of 786-O cells was assessed using a WST-1 kit (Beyotime, Haimen, China), according to the manufacturer's instructions. After lentivirus infection, the cells were seeded in 6-well plates and incubated at 37˚C. Cell proliferation was assessed based on the absorbance measured at 450 nm using a multiwell spectrophotometer (Eppendorff, Hamburg, Germany).
Wound healing assay. After lentivirus infection, 786-O cells were seeded at 5x10
5 cells/well in 6-well plates and cultured in RPMI-1640 medium supplemented with 10% FBS for ~24 h to near confluence. The cell monolayer was scraped in a straight line using a 20 µl pipette tip to create a scratch, and the medium was changed to remove detached cells. Images were captured at 0, 6, 12 and 24 h after scratching and analyzed using the Image J program to calculate cell migration distance. Cells from six representative fields were counted.
Flow cytometry analysis of apoptosis. Apoptosis was evaluated using annexin V/propidium iodide (PI; BD-Biosciences, San Jose, CA, USA) staining followed by flow cytometry analysis. After lentivirus infection, the cells were plated in 6-well plates at a density of 1x10 6 cells/well, cultured at 37˚C in a 5% CO 2 incubator for three days, then gently trypsinized and washed with ice-cold PBS. The cells were resuspended in 500 µl 1X binding buffer and stained with annexin V and PI. The samples were subjected to flow cytometry analysis within 1 h using a flow cytometer (BD LSRⅡ; BD-Biosciences) and the data were analyzed using BD FACS Diva software (BD-Biosciences).
Microarray analysis. Total RNA was extracted from 786-O cells using TRIzol (Invitrogen), according to the manufacturer's instructions, and purified with an RNeasy Mini kit (Qiagen, Mississauga, Ontario, ON, Canada). The integrity of the purified RNA was examined using agarose gel electrophoresis, and the quality and quantity of purified RNA were assessed using an Agilent 2100 Bioanalyzer RNA 6000 NanoChip (Agilent, Palo Alto, CA, USA). Only RNA samples with an A260/A280 between 1.7 and 2.2 were used in further experiments. Total RNA (5 µg) was used to generate cDNA, which was labeled with the NimbleGen one-color DNA labeling kit (Roche NimbleGen, Madison, WI, USA). The labeled cDNA was hybridized in a NimbleGen human gene expression 12x135 K microarray (Roche NimbleGen, Madison, WI, USA), according to the manufacturer's instructions. The washed arrays were spin-dried and scanned using the Genepix 4000B scanner (Axon Instruments, Union City, CA, USA).
Microarray data analysis. Images were extracted and processed using NimbleScan v2.4 software and analyzed using the NimbleGen software (both Roche NimbleGen). The lognormal-normal model was employed in order to estimate the expression of each gene. Genes were ranked according to this value and the results were filtered further according to the magnitude of the change in expression; only genes that were at least 2-fold upregulated or downregulated were considered. Gene Ontology (GO) analysis for the differentially expressed genes was performed by using DAVID (http://david.abcc. ncifcrf.gov/. Accessed April 18, 2013), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using the Ingenuity Pathway Analysis software package (IPA; Ingenuity Systems, Redwood City, CA, USA).
Statistical analysis.
Values were represented as the means ± SD for at least triplicate determination, and analyzed using one-way ANOVA and an LSD test. All statistical analyses were performed using SPSS 13.0, where P<0.05 was considered to indicate a statistically significant difference.
Results

Evaluation of CLU knockdown in 786-O cells.
To verify that the CLU-RNAi lentivirus efficiently knocked down CLU in 786-O cells, we performed real-time PCR analysis to detect CLU mRNA levels in 786-O cells transduced by a different CLU-RNAi lentivirus and a negative control lentivirus. The results demonstrated that no. 3 CLU RNAi was most the efficient at reducing the CLU mRNA levels (data not shown). We performed western blot analysis to detect the CLU protein levels in the 786-O cells transduced by a different lentivirus. The results demonstrated that no. 3 CLU RNAi was the most efficient at reducing the CLU protein levels (Fig. 1) , consistent with real-time PCR results. Therefore, we chose Prostate cancer  AKT3, CREB3L2, EGFR, MDM2, PDGFC, PDPK1, PIK3CD, RB1  mTOR signaling pathway  AKT3, DDIT4, PDPK1, PIK3CD, RICTOR, RPS6KA2, VEGF  MAPK signaling pathway  AKT3, ATF2, CASP3, DUSP5, EGFR, FGF5, IL1R1, MAP3K7IP2,  MAP3K8, MAPK14, MAPKAPK2, NF1, PRKACB, PRKCA, RAP1B,  RAPGEF2, RPS6KA2  Melanoma  AKT3, CDK6, EGFR, FGF5, MDM2, MITF, PDGFC, PIK3CD, RB1  Non-small cell lung cancer  AKT3, CDK6, EGFR, PDPK1, PIK3CD, PRKCA, RB1, RXRA  Chronic myeloid leukemia  AKT3, CBLB, CDK6, MDM2, PIK3CD, RB1, RUNX1  Aldosterone regulated sodium reabsorption ATP1A1, ATP1A1, PDPK1, PIK3CD, PRKCA  Pathways in cancer  AKT3, AXIN2, CASP3, CBLB, CCDC6, CDK6, CUL2, EGFR, EGLN1, FGF5,  FN1, GLI2, KITLG, MDM2, MITF, PIAS2, PIK3CD, PRKCA, RB1, RUNX1,  RXRA, VEGF, WNT5A no. 3 CLU RNAi to knockdown CLU in 786-O cells in subsequent experiments.
CLU knockdown inhibits the proliferation of RCC cells.
To investigate whether CLU regulates the proliferation of RCC cells, 786-O cells were infected with either an si-CLU lentivirus or a control lentivirus, and cell proliferation was evaluated with a WST-1 assay. The results revealed that CLU knockdown reduced the proliferation of 786-O cells over the 72 h period (Fig. 2A) .
The effect of CLU knockdown on apoptosis in RCC cells.
Flow cytometry analysis revealed that the apoptotic ratio was 6.30±3.17% in 786-O cells infected by the si-CLU lentivirus, which was significantly lower than that in cells infected by the negative control lentivirus (1.20±0.40%) or uninfected cells (1.01±0.37%; Fig. 2B ). These results suggest that CLU plays an anti-apoptotic role to promote the proliferation of RCC cells.
CLU knockdown inhibits the migration of RCC cells.
To investigate whether CLU regulates the migration of RCC cells, an important behavior involved in RCC metastasis, 786-O cells were infected with either an si-CLU lentivirus or a control lentivirus, and cell migration was evaluated using a wound healing assay. We observed that CLU knockdown reduced the migration of 786-O cells at 12 and 24 h after scratches were created (Fig. 3) , suggesting that CLU promotes the migration and invasion of RCC cells. (Fig. 4) . These differentially expressed genes were distributed in almost all chromosomes, with the exception of the Y chromosome, but were enriched in chromosome 1 (9.97%), chromosome 2 (7.58%), chromosome 6 (5.92%), chromosome 11 (8.1%), chromosome 14 (5.4%) and chromosome 19 (5.92%).
CLU knockdown leads to differential gene expression in
We performed GO and KEGG pathway analyses to classify the differentially expressed genes in the 786-O cells after CLU knockdown. The results demonstrated that 17 pathways were upregulated and 12 were downregulated (Table I) .
Discussion
CLU is overexpressed in a variety of tumors and promotes tumorigenesis. Furthermore, 3-CLU has been proposed as a prognostic marker for RCC (10) . A recent study reported that an antisense oligodeoxynucleotide targeting clusterin exhibited antitumor activity in an RCC model (11) . These studies suggest that CLU plays an oncogenic role in RCC. Consistent with this theory, in the present study, we employed a loss-of-function approach to knockdown CLU in the 786-O cell line and observed that CLU knockdown induces apoptosis and inhibits the proliferation and migration of 786-O cells. These results provide further evidence for the oncogenic role of CLU in RCC. However, the detailed molecular mechanisms by which CLU promotes RCC development remain largely unknown.
Cancer development is known to be a multi-step process involving sequential changes in a variety of genes and cellular pathways (12) . Microarray techniques have been applied widely in cancer research due to their advantages in revealing the dynamics of gene expression and gene regulation networks from a global perspective, which contributes to our understanding of cancer initiation, progression and metastasis (9, 13, 14) .
In this study, we used a NimbleGen microarray to screen the differentially expressed genes in 786-O cells after CLU knockdown vs. the parental 786-O cells. We revealed that 356 genes were upregulated and 232 were downregulated. Although these differentially expressed genes were distributed in almost all chromosomes, with the exception of the Y chromosome, they were relatively enriched in chromosomes 1, 2, 6, 11 and 14, consistent with previous molecular genetics studies on RCC. For example, Beroukhim et al (15) identified 7 regions of deletion (1p, 3p, 4q, 6q, 8p, 9p and 14q) in hereditary and sporadic clear-cell RCC. Moreover, Monzon et al (16) identified deletions in chromosomes 1, 5, 6, 9, 13 and 14 in renal cancer patients.
Furthermore, we classified the differentially expressed genes into different biological pathways in order to characterize their functional role in RCC. As expected, approximately half of the downregulated pathways are cancer-related, including the PI3K/Akt, MAPK and VEGF pathways, known to promote cancer cell proliferation, survival and tumor angiogenesis and metastasis. After CLU knockdown, the downregulation of these pathways may have contributed to the observed inhibition of 786-O cell proliferation and migration. Notably, we identified that a number of pathways involved in immunity and infection were upregulated. Future studies exploring the correlation between RCC development and immunological function may shed new light on the functional role of CLU in tumorigenesis.
In conclusion, this study presents evidence that CLU acts as an oncogene in RCC by promoting cancer cell proliferation and migration and inhibiting cancer cell apoptosis. We identified differentially expressed genes after CLU knockdown and classified them according to their related biological pathways. Our findings provide a platform for further characterization of the individual genes implicated in RCC development, which may provide new insights into the oncogenic role of CLU.
